Skip to content
Review

Abstract 15621: Safety, Efficacy, and Renal Effects of Baxdrostat in Controlled versus Resistant Hypertension: A Systematic Review and Meta-Analysis

Nov 2026 · Circulation · 0 citations

Abstract

Background: Hypertension, particularly resistant hypertension, persists as a major global burden associated with significant challenges in therapeutic management. Baxdrostat, a selective aldosterone synthase inhibitor, can be investigated as a potential therapy for blood pressure treatment. We conducted a meta-analysis comparing baxdrostat with a placebo in uncontrolled hypertensive patients and resistant hypertensive patients separately. Research Question: What are the efficacy, renal, and safety outcomes of baxdrostat compared with placebo in patients with resistant versus uncontrolled hypertension? Methods: PubMed, Cochrane, Scopus, and Embase databases were systematically searched from inception to May 1, 2026. Primary outcomes were efficacy and renal outcomes. Aldosterone-relevant biomarkers (serum aldosterone, urinary aldosterone, and plasma renin) and safety outcomes were also assessed. Dichotomous outcomes were analyzed using risk ratio (RR) with 95% confidence intervals (CI), while continuous outcomes used mean differences (MDs). Results: A total of 6 RCTs comprising 1778 patients were included. In patients with resistant hypertension, baxdrostat significantly reduced mean seated systolic blood pressure (SBP) (MD -14.15; 95% CI -17.44 to -10.86; p<0.00001) and diastolic blood pressure (DBP) (MD -4.86; p<0.0001). Furthermore, significant reductions in 24-hour ambulatory SBP (MD -14.27mmHg) and night-time SBP (MD -13.50; both p<0.00001) were noted. Renal outcomes showed a significant eGFR decrease (MD -7.41; p<0.00001) and an increased risk of ≥30% eGFR decline (RR 6.82; p<0.00001). Safety analysis revealed a higher risk of any adverse events (RR 1.17; p=0.03) and hyperkalemia (RR 9.10; p=0.01), specifically for potassium >5.5 mEq/L (RR 6.70; p=0.002). No significant risk was found for serious adverse events or potassium >6.5 mEq/L. In the uncontrolled hypertension group, baxdrostat did not significantly reduce mean seated SBP (MD -4.71 mmHg; 95% CI -11.60 to 2.17; p=0.18) or DBP (MD 0.25; 95% CI -1.65 to 2.16; p=0.79). The likelihood of achieving an SBP target <130 mmHg was also non-significant (RR 1.43; p=0.33). However, baxdrostat significantly lowered serum aldosterone (MD -2.85; 95% CI -4.30 to -1.40; p=0.0001) and increased plasma renin (MD 2.30; 95% CI 0.12 to 4.47; p=0.04). No significant increases were observed for any adverse events, serious adverse events, hyperkalemia, or hypotension. Conclusion: Baxdrostat is highly effective in reducing blood pressure in resistant hypertension but is associated with risks of hyperkalemia and acute eGFR decline. In contrast, it provides no significant blood pressure benefit in uncontrolled hypertension despite aldosterone suppression. While a potential option for resistant cases, its use requires careful renal monitoring.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.